Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by G1945Von Sep 05, 2023 10:29am
76 Views
Post# 35619727

RE:RE:RE:RE:Financing Was Obvious and Inevitable

RE:RE:RE:RE:Financing Was Obvious and Inevitable
Speyeder999 wrote: This might clear up some misconceptions.

I don't like it any better than most of you and am still thinking some form of machiavellian scheme took place, but it does seem to shed a little more light on what may have transpired.

The missed milestones, erroneuos coorporate overviews/updates and silent treatment before/after FDA approval WERE REAL, not conspiracy theories.


https://www.investopedia.com/ask/answers/05/sharestradedoutstanding.asp#:~:text=The%20number%20of%20shares%20traded,have%20a%20relatively%20small%20float.


"Day traders will often buy and sell shares of the same company multiple times during the same trading session, thus increasing the trading volume so that it exceeds the number of outstanding shares."

That explains it—the market in a fit of frenzy.


G1945V
<< Previous
Bullboard Posts
Next >>